GlassScriptPhysician profile
Calah Rea Raab
NPI 1245941806
$2,521.11
in general payments reported to CMS, 2019-2025
28 companies · $995 in 2025
The $995 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $231 · 2023: $449 · 2024: $845 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.61 |
| Education | $303.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.59 | 2022-2024 | Ozempic |
| Pfizer INC. | $257.42 | 2025 | |
| Astellas Pharma US INC | $254.59 | 2023-2025 | Xospata |
| Evofem Biosciences, INC. | $184.18 | 2022-2023 | Phexxi |
| Springworks Therapeutics, INC. | $144.52 | 2025 | Gomekli |
| Phathom Pharmaceuticals, INC. | $125.24 | 2025 | Voquezna |
| Kiniksa Pharmaceuticals International, Plc | $118.08 | 2024 | Arcalyst |
| Neurocrine Biosciences, INC. | $114.23 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $113.59 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $107.43 | 2023-2024 | Dificid, Prevymis, Keytruda |
| Daiichi Sankyo INC. | $90.98 | 2023-2024 | Vanflyta |
| Amarin Pharma, INC. | $89.62 | 2025 | Vascepa |
| Sobi, INC | $64.02 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $62.32 | 2025 | Breyanzi |
| Genmab U.S., INC. | $53.42 | 2023-2024 | Epkinly |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $52.57 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $51.52 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.62 | 2023-2024 | Iclusig |
| Incyte Corporation | $45.38 | 2023-2024 | Pemazyre, Monjuvi |
| Melinta Therapeutics, LLC | $40.68 | 2024 | Rezzayo, Kimyrsa |
| Seagen INC. | $35.96 | 2023 | Adcetris |
| Amgen INC. | $32.12 | 2023 | Kyprolis, Blincyto |
| Genentech USA, INC. | $30.27 | 2023 | Venclexta |
| Alexion Pharmaceuticals, INC. | $27.35 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $25.59 | 2024 | Besremi |
| Celgene Corporation | $20.04 | 2023 | Reblozyl |
| Eisai INC. | $18.43 | 2025 | |
| Emd Serono, INC. | $13.35 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calah Raab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.